Open Access
CC BY 4.0 · Arq Neuropsiquiatr 2023; 81(S 01): S1-S96
DOI: 10.1055/s-0043-1774616
CASE REPORT
Neuroimunologia, esclerose múltipla e outras doenças desmielinizantes
Code: PE172

Guillain-Barre Syndrome: Case Series

Layanna Bezerra Maciel Pereira
1   Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
,
Renata Yasmin Cardoso Sousa
1   Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
,
Lygia Ohlweiler
1   Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
,
Dayana de Lima Mariano
1   Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
,
Michele Michelin Becker
1   Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
,
Maria Isabel Bragatti Winckler
1   Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
,
Gabriel de Lellis Neto
1   Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
,
Hugo Leonardo Justo Horácio
1   Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
,
Josiane Ranzan
1   Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
› Institutsangaben
 

    Case presentation: Guillain-Barré Syndrome (GBS) is an acute polyradiculopathy that occurs frequently following infectious diseases, which can lead to an immune response to nerve antigens, resulting in demyelination and/or axonal damage. Below, we will report 4 clinical cases of GBS associated with previous SARS-Cov-2 in pediatric patients. One patient was diagnosed with COVID by PCR testing and three with serology testing. Two patients had previous comorbidities – one had Cantu Syndrome and another had Glycogenosis type Ib. The diagnosis of GBS was confirmed by albuminocitologic dissociation in the cerebrospinal fluid in 3 cases, electroneuromyography with demyelination pattern in all 4 cases, and one patient had brain magnetic resonance imaging showing contrast enhancement in the cauda equina e medullary cone, compatible with inflammatory process. The patients with previous comorbidities evolved with respiratory failure and required mechanical ventilation. 3 patients received intravenous immunoglobulin (IVIg), with adequate response. One of them required two IVIg cycles.

    Discussion: The association between GBS and coronaviruses has been previously reported following such infections, including MERS-Cov (KIM et al., 2017) and, more recently, SARS-CoV-2. COVID-19 causes an exaggerated immune response with persistent fever, elevated inflammatory markers and pro-inflammatory cytokines. It is likely an immune dysregulation caused by COVID-19 that increases the risk of immune mediated conditions, such as GBS. It can occur as classic post-infectious disease or as part of the already reported Long COVID-19 Syndrome. The majority of reported cases begin acutely a few days after the viral infection.

    Final comments: In neurologic presentations compatible with GBS in pediatric patients, we must consider previous or acute SARS-Cov-2 infection as the possible etiology.


    Die Autoren geben an, dass kein Interessenkonflikt besteht.

    Publikationsverlauf

    Artikel online veröffentlicht:
    18. September 2023

    © 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

    Thieme Revinter Publicações Ltda.
    Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil